Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 04, 2019 22:00 ET | Source: AnGes MG, Inc.

AnGes Obtains Conditional Approval in Japan for HGF Gene Therapy to Treat Critical Limb Ischemia

TOKYO, April 05, 2019 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for treating serious diseases, announced today that they have...
July 31, 2018 07:00 ET | Source: AnGes MG, Inc.

Vasomune Therapeutics and AnGes, Inc. enter into a Multi-Million Dollar Global Co-Development Agreement to Advance an Innovative Platform Targeting Vascular Leakage

TOKYO and TORONTO, July 31, 2018 (GLOBE NEWSWIRE) -- Vasomune Therapeutics (“Vasomune”), a Toronto-based spin-out from Sunnybrook Research Institute and MaRS Innovation, and AnGes, Inc. (Tokyo,...
February 27, 2018 19:31 ET | Source: AnGes MG, Inc.

AnGes Announces First Patient Treated with NF-kappa B Decoy in Phase Ib Study to Treat Discogenic Low Back Pain

TOKYO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for serious diseases, announced today the treatment of the...
January 22, 2018 22:11 ET | Source: AnGes MG, Inc.

AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia

TOKYO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for serious diseases, announced today the submission of an...
October 05, 2014 20:20 ET | Source: AnGes MG, Inc.

AnGes Starts Global Phase III Clinical Trials of Collategene(R) for Critical Limb Ischemia

TOKYO, Oct. 6, 2014 (GLOBE NEWSWIRE) -- AnGes MG, Inc. ("AnGes") announces that it has commenced the global phase III clinical trials of Collategene® with the enrollment of patients in the...
October 23, 2012 23:00 ET | Source: AnGes MG, Inc.

AnGes Enters Into the Definitive Agreement With Mitsubishi Tanabe Pharma for Exclusive Marketing Rights of Collategene(R) in the United States

TOKYO, Oct. 24, 2012 (GLOBE NEWSWIRE) -- AnGes MG Inc. ("AnGes") announced today that the company has entered into a definitive agreement with Mitsubishi Tanabe Pharma Corporation (Head Office:...